Central nervous system (CNS) tumors are the second most common childhood cancer, and over 75% of children diagnosed survive long-term. Among childhood cancer survivors, pediatric CNS tumor survivors are at the highest risk for late mortality, new chronic medical conditions and poor health-related quality of life (HRQOL). Horrifically, cumulative late mortality amongst pediatric CNS tumor survivors is more than 26% at 30 years. New tumor treatment strategies as well as interventions to improve long-term morbidity and mortality for this population are fervently needed.
Our field is progressing in its appreciation of the interconnectedness between physical, psychosocial, cognitive health, and quality of life amongst survivors. Deficits in physical performance not only impact medical health, but limit potential for social accomplishments and overall well-being. In addition, most pediatric CNS tumor survivors suffer from neurocognitive impairment due to disturbances in brain anatomy, circuity, and function. Neurocognitive impairment, regardless of physical health, is significantly and independently associated with reduced attainment of social milestones.
The overall aim for this Research Topic is to focus on innovative methods to understand, mitigate and/or prevent pediatric CNS tumor late effects. We welcome studies in various article types including Original Research, Perspectives, Reviews, Mini Reviews.
The contents covered in this Research Topic include but are not limited to the following subtopics:
- Non-tumor neurobiological changes secondary to diagnosis and treatment
- Relationship of biological changes to developmental behavior
- Environmental mediators of outcomes, from diagnosis through survivorship
- Novel interventions during and after tumor treatment aimed to improve cognitive, socio-emotional, physical, and/or financial health
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Central nervous system (CNS) tumors are the second most common childhood cancer, and over 75% of children diagnosed survive long-term. Among childhood cancer survivors, pediatric CNS tumor survivors are at the highest risk for late mortality, new chronic medical conditions and poor health-related quality of life (HRQOL). Horrifically, cumulative late mortality amongst pediatric CNS tumor survivors is more than 26% at 30 years. New tumor treatment strategies as well as interventions to improve long-term morbidity and mortality for this population are fervently needed.
Our field is progressing in its appreciation of the interconnectedness between physical, psychosocial, cognitive health, and quality of life amongst survivors. Deficits in physical performance not only impact medical health, but limit potential for social accomplishments and overall well-being. In addition, most pediatric CNS tumor survivors suffer from neurocognitive impairment due to disturbances in brain anatomy, circuity, and function. Neurocognitive impairment, regardless of physical health, is significantly and independently associated with reduced attainment of social milestones.
The overall aim for this Research Topic is to focus on innovative methods to understand, mitigate and/or prevent pediatric CNS tumor late effects. We welcome studies in various article types including Original Research, Perspectives, Reviews, Mini Reviews.
The contents covered in this Research Topic include but are not limited to the following subtopics:
- Non-tumor neurobiological changes secondary to diagnosis and treatment
- Relationship of biological changes to developmental behavior
- Environmental mediators of outcomes, from diagnosis through survivorship
- Novel interventions during and after tumor treatment aimed to improve cognitive, socio-emotional, physical, and/or financial health
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.